HomeBiosceptre2019-12-21T11:22:17+11:00

Biosceptre_P2X7_Model-home_530x650px

Promise beyond cancer

Pioneering the development of nfP2X₇ targeted therapeutics

Biosceptre is a biopharmaceutical company developing targeted therapeutics and immune-oncology products against non-functional P2X₇ (nfP2X₇), a cancer target that has been shown to be present on the majority of cancers. Our goal is to bring novel therapeutics to patients suffering from a wide range of malignancies.

What is nfP2X₇?

SPECIFIC

to cancer cells

Non-functional P2X₇ is a cell receptor highly specific to cancer cells.

TARGETED

to more than 20 cancer types

nfP2X₇ is present on more than 20 of the most common cancers including: breast, lung, colorectal, and prostate.

THERAPEUTICS

with multiple modalities

Drug therapies in the pipeline include CAR-T and systemic antibodies.

Biosceptre_Team_Gavin-Currie

Biosceptre Team

“Biosceptre has built a team of highly talented and motivated people, focused on delivering our vision – a promise beyond cancer.”

– Gavin Currie, CEO Biosceptre International

News & Media

Biosceptre attending J.P. Morgan Healthcare Conference in January 2020

Biosceptre attending J.P. Morgan Healthcare Conference in January 2020

Biosceptre Board Changes as result of Sir Gregory Winter’s Nobel Prize

Biosceptre Board Changes as result of Sir Gregory Winter’s Nobel Prize

Biosceptre wins Gold Medal at China’s largest event for promoting innovation and entrepreneurship

Biosceptre wins Gold Medal at China’s largest event for promoting innovation and entrepreneurship